Gain Therapeutics
GANX
24 hedge funds and large institutions have $5.05M invested in Gain Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
86% more call options, than puts
Call options by funds: $54K | Put options by funds: $29K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
2% more capital invested
Capital invested by funds: $4.95M → $5.05M (+$100K)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4.37% less ownership
Funds ownership: 11.93% → 7.57% (-4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$84.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$54.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.3K |
| 4 |
Millennium Management
New York
|
+$35.5K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$31.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$85.4K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$36.2K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$27.8K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$27.1K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Simplex Trading
Chicago,
Illinois
| – | -$24K | -8,650 | Closed |
|
|
HGERS
27
Householder Group Estate & Retirement Specialist
Scottsdale,
Arizona
| – | -$8.2K | -2,500 | Closed |
|
GANX Hedge Fund Activity: Q4 2023 in Review
24 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q4 2023, worth a combined $5.05M — up 2% from $4.95M a quarter earlier.
Fund positioning in GANX was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 6 trimmed.
The largest buyer was Northern Trust, adding an estimated $84.1K. The largest seller was Susquehanna International Group, cutting an estimated $85.4K.
- 24 institutional investors held Gain Therapeutics (GANX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $5.05M of Gain Therapeutics stock for Q4 2023, up 2% quarter-over-quarter.
- 3 funds opened new Gain Therapeutics positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Gain Therapeutics buyer in Q4 2023 was Northern Trust, an estimated $84.1K added.
- The largest Gain Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $85.4K sold.
Based on aggregated 13F filings for Q4 2023.